Penn Pancreatic Cancer Research Center

A multidisciplinary clinic is held weekly as part of the Penn Pancreatic Cancer Research Center

Clinical Trials

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or Patricia.Gambino@uphs.upenn.edu to make an appointment with one of our Oncologists to discuss clinical trials. 

Neoadjuvant Trials — Pre-operative

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 20214 (NCT02588443) CD40 agonist mAb in combination with Nab-Paclitaxel and Gemcitabine Chemotherapy /Immunotherapy Phase I Study of Neo-adjuvant RO7009789 alone or Neu-adjuvant RO7009789 plus Nab-Paclitaxel and Gemcitabine followed by Adjuvant RO7009789 plus Nab-Paclitaxel and Gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma Robert H. Vonderheide, MD, D.Phil.
Adjuvant Trials — Post-operative

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 03213 Folfirinox vs. Gemcitabine/ nab®-Paclitaxel Radiotherapy & Chemotherapy A randomized Phase II/genomic trial of two chemotherapy regimens in patients with resected pancreatic adenocarcinoma. Peter O’Dwyer, MD
UPCC 22913 hTERT Immunotherapy A study of hTERT immunotherapy alone or in combination with IL-12 DNA followed by electroporation in adults with breast, lung, or pancreatic cancer at high risk of relapse post definitive surgery and adjuvant therapy Robert H. Vonderheide, MD, D.Phil.
UPCC 26213 (NCT01845805) Oral azacitidine Epigenetic Therapy A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy Peter O’Dwyer, MD
Locally Advanced

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 32213 Radiation & nab®-Paclitaxel Radiation & Chemotherapy A phase I dual dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer Edgar Ben-Josef, MD
Metastatic trials-First Line (Initial treatment for newly metastatic diagnosis)

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 11217 Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab Chemotherapy combined with Immunotherapy The main purposes of this study are to learn how effective the study drug combinations are in treating patients with previously untreated metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel Mark O’Hara, MD

Maintenance Therapy

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 05217 (NCT03140670)

Rucaparib Phosphate in Treating Patients with Advanced Pancreatic Cancer and a Known Deleterious BRCA1/2 or PALB2 Mutation

Targeted Therapy A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation Kim Reiss Binder, MD
Metastatic Trials — Second Line

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 23915 (NCT02639026) Hypofractionated Radiotherapy in combination with MEDI4736 and Tremelimumab Immunotherapy /Radiotherapy Phase I trial of Hypofractionated radiotherapy in combination with MEDI4736 Tremelimumab for patients with metastatic melanoma and lung, breast, and pancreatic cancers Mark O'Hara, MD
Metastatic Trials — Third Line

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 23915 (NCT02639026) Hypofractionated Radiotherapy in combination with MEDI4736 and Tremelimumab Immunotherapy /Radiotherapy Phase I trial of Hypofractionated radiotherapy in combination with MEDI4736 Tremelimumab for patients with metastatic melanoma and lung, breast, and pancreatic cancers Mark O'Hara, MD
Biomarker Trials

Trial #

Trial

Type of therapy

Description

Principal Investigator

UPCC 22210 Pancreatic Tissue Acquisition No Therapy Protocol to permit the acquisition of samples of tumor and normal tissue for biological endpoints in pancreatic cancer Peter O`Dwyer, MD
UPCC 02215 Circulating Tumor Material No Therapy Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases and Control Subjects Peter O`Dwyer, MD

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or patricia.gambino@uphs.upenn.edu to make an appointment with one to discuss clinical trials.

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.